130 results about "Formononetin" patented technology

A UGT2B inhibitor capable of increasing the bio-availability of a drug, is a compound in a free base or a pharmaceutically acceptable salt form that is selected from the group consisting of: capillarisin, isorhamnetin, β-naphthoflavone, α-naphthoflavone, hesperetin, terpineol, (+)-limonene, β-myrcene, swertiamarin, eriodictyol, cineole, apigenin, baicalin, ursolic acid, isovitexin, lauryl alcohol, puerarin, trans-cinnamaldehyde, 3-phenylpropyl acetate, isoliquritigenin, paeoniflorin, gallic acid, genistein, glycyrrhizin, protocatechuic acid, ethyl myristate, umbelliferone, PEG (Polyethylene glycol) 400, PEG 2000, PEG 4000, Tween 20, Tween 60, Tween 80, BRIJ® 58, BRIJ® 76, Pluronic® F68, Pluronic® F127, and a combination thereof. A UGT2B enhancer capable of enhancing a clearance rate of morphine-like analgesic agents, is a compound in a free base or a pharmaceutically acceptable salt form that is selected from the group consisting of: nordihydroguaiaretic acid, wogonin, trans-cinnamic acid, baicalein, quercetin, daidzein, oleanolic acid, homoorientin, hesperetin, narigin, neohesperidin, (+)-epicatechin, hesperidin, liquiritin, eriodictyol, formononetin, quercitrin, genkwanin, kaempferol, isoquercitrin, (+)-catechin, naringenin, daidzin, (−)-epicatechin, luteolin-7-glucoside, ergosterol, rutin, luteolin, ethyl myristate, apigenin, 3-phenylpropyl acetate, umbelliferone, glycyrrhizin, protocatechuic acid, poncirin, isovitexin, 6-gingerol, cineole, genistein, trans-cinnamaldehyde, and a combination thereof.

This invention is to provide multiple specific inhibitors of cytochrome P450 isozyme CYP2C9. These inhibitors can be derived from any combinations with the following compounds including: Tamarixetin, Formononetin, isoliquritigenin, Phloretin, luteolin, Quercitrin, quercetin, myricetin, Wongonin, Puerarin, Genistein, Nordihydroguaiaretic acid, Narigenin, Capillarisin, Chrysin, Fisefin, eriodictyol, 6-Gingerol, Isorhamneti, isoquercitrin, Morin, (+)-Taxifolin, isovitexin, 3-Phenylpropyl Acetate, Oleanolic acid, ursolic acid, β-Myrcene, cinnamic acid, Luteolin-7-Glucoside, Liquiritin, (+)Limonene, Homoorientin, Swertiamarin, Embelin, Daidzein, Poncirin, (−)-Epicatechin, ergosterol. These natural products can be used to enhance the bioavailability of therapeutic agents (drugs).

The invention belongs to heterocyclic compound technical field, concretely relating to a heterocyclic compound in which unhydrogenated six-member heterocyclic ring containing an only ring hetero atom of an oxygen atom fuses with other phenyl rings. The invention provides a synthetic method of an isoflavone compound. The method comprises the steps of adding a reactant (substituted) 3-iodine chromone and tetraarylated tin into a solvent for a chemical reaction, and using column chromatography and recrystallization methods to purify the above resultant to obtain the pure compound of the present invention. By using the method, medicinal isoflavone such as daidzein, genistein, Ipriflavone, puerarin, formononetin and the like is prepared, and a new technical route of industrialization production of the above medicaments is established. Simultaneously, a series of novel isoflavone compounds with potential physiological activity are prepared.

The invention discloses a novel use of formononetin in pharmacy, and in particular discloses an application of formononetin in preparing a medicine for treating breast cancer. The applicants discover that formononetin can remarkably inhibit cell proliferation of breast cancer for the first time and discover through experiments that formononetin retards cell cycle by way of inactivating IGF1/IGF1R-PI3K/AKT, so that formononetin generates good activity of inhibiting cell proliferation of breast cancer, and can be used as a cell cycle retardant to replace tamoxifen to inhibit cell proliferation of breast cancer so as to prevent and treat breast cancer. In addition, the applicants in experiments further discover that formononetin can be used as the cycle retardant for cancer cells and has specific targeting to normal cells as an agonist, so that formononetin has very high development value and real application value.

The invention relates to bacillus amyloliquefaciens and a method for preparing succinyl ononin in a nonaqueous phase, and belongs to the technical field of biological catalysis. The bacillus amyloliquefaciens is named bacillus amyloliquefaciens FJ18. The preservation unit is China Center for Type Culture Collection (CCTCC), and the preservation number is CCTCC NO: M2016272. The invention also provides a method for preparing succinyl ononin in a nonaqueous phase by the strain. The strain can effectively catalyze fermlononetin to prepare succinyl ononin. Thus, the problem of scarcity of formononetin glucoside compounds is solved.

The invention relates to a novel application of formononetin in the medical science, in particular to the application of formononetin in preparing medicine for preventing and treating airway inflammation and asthma. Pharmacological test result shows that the formononetin participates in reducing the allergic airway inflammation of model animals/occurring and developing of asthma lesion; reducing the of damage inflammatory factor to the human bronchial epithelial cell in vitro and the formononetin can be used for preparing the medicine for treating airway inflammation diseases, such as asthma, bronchitis, capillary bronchitis and air or non-air idiotoxin or inflammatory or non-inflammatory of irritant; and specifically, the formononetin has the application in preparing medicine for treating allergic airway inflammation and asthma disease.

The invention relates to an extraction and purification method of licoflavone ingredients, and belongs to an extraction and purification method of licoflavone ingredients in plants. Liquorice roots are used as raw materials and are extracted by distilled water to obtain a liquorice root extraction solution; then, through methanol and ethyl acetate treatment, the flavone ingredients in the liquorice roots are coarsely separated; a DM130 macroporous resin and polyamide resin combined column passing method is used; finally, high performance liquid-mass spectrometry is used for performing ingredient identification on the purified flavone ingredients. The method has the beneficial effects that the DM130 macroporous resin and polyamide resin combined method is for better separating and purifyingthe lavone ingredients in the liquorice roots; in addition, the influence of saponin ingredients is reduced to the minimum; the pharmacodynamic study and the like on flavone ingredients in the liquorice roots are facilitated; the licoflavone identified by the liquid chromatography-mass spectrometry is mainly glycyrrhizin glucoside, liquiritin, isolicorice glucoside, isoliquiritin, glycyrrhizin, isoliquiritigenin, formononetin, glicoricone, glycyrrhizic acid and glycycoumarin.

The invention discloses a formononetin derivative comprising dithiocarbamate, and a preparation method and application of the formononetin derivative to antitumor drugs, and belongs to the field of pharmaceutical chemistry. The mother nucleus of formononetin is combined with a dithiocarbamate active unit to simply, efficiently and greenly synthesize the formononetin derivative comprising dithiocarbamate. The general molecular formula of the formononetin derivative comprising dithiocarbamate is shown in the description. The in vitro antitumor activity test of the compound indicates that the formononetin derivative has a certain effect of inhibiting multiple tumor cells of EC-109, MGC-803 and PC-3. Compared with the natural formononetin, the anti-prostate cancer activity of the formononetin derivative I-8 comprising dithiocarbamate is improved by 28 times, so that the formononetin derivative comprising dithiocarbamate is a candidate or a lead compound for further development, and is applied to the preparation of the antitumor drugs.

The invention relates to a content determination method for multiple components in a Yupingfeng preparation. The method comprises the steps of: (1) taking the Yupingfeng preparation, crushing or not crushing it, then performing precise weighing, adding methanol to conduct reflux extraction for 1-3h, carrying out filtration and concentration, then adding methanol to a constant volume, thus obtaining a test solution; (2) precisely weighing the reference substance prim-o-glucosylcimifugin, calycosin-7-glucoside, cimifugin, 5-O-methylvisammioside, sec-o-glucosylhamaudol, calycosin, formononetin, atractylenolide III, atractylenolide I and atractylenolide II respectively, and adding methanol to perform dissolving to a constant volume, thus obtaining a mixed reference solution; (3) conducting determination: precisely sucking the test solution and the mixed reference solution respectively, injecting them into a high performance liquid chromatograph, carrying out gradient elution under certain mobile phase condition, and performing multi-wavelength simultaneous monitoring, thus obtaining the content. The method provided by the invention can accurately determine the content of 10 components in the Yupingeng preparation, and can objectively, comprehensively and sensitively reflect the quality condition of the Yupingfeng preparation.

The invention provides a method for simultaneously detecting main components, including puerarin, formononetin, paeoniflorin, tanshinone II A and cryptotanshinone, of a compound Danlou tablet in a plasma sample with the HPLC-MS/MS method. In a liquid chromatogram, a flow phase is composed of acetonitrile and a formic acid aqueous solution 0.1% in volume fraction, and gradient elution is adopted. A positive ion-negative ion rapidly-switching analysis mode and an MRM scanning mode are adopted for a mass spectrum. After the Danlou tablet is dosed, change conditions of the blood concentrations of the main components in the rat plasma are simultaneously detected. The methodology inspection result shows that the built method meets inner-body biological sample detecting requirements and is good in sensitivity, high in specificity, stable, reliable and suitable for detecting substance low in content.

Disclosed herein are processes for the preparation of isoflavonoids, in particular haginin E, equol, daidzein, formononetin and the like, in which 7-benzyloxy-3-(4-methoxyphenyl)-2H-1-benzopyran is used as a common starting material.

The invention belongs to the technical field of heterocyclic compounds, and particularly relates to a heterocyclic non-hydrogenated heterocyclic compound containing a six-membered ring and taking an oxygen atom as the only heteroatom and condensed with other rings. The invention provides a new method for synthesizing isoflavone by a nickel-catalyzed Negishi cross coupling reaction at room temperature, which comprises the following steps of: adding reactants (substituted) 3-iodine chromone or (substituted) 3-bromine chromone and an aryl zinc reagent into a solvent, and performing a nickel-catalyzed reaction at room temperature; and after the reaction, performing column chromatographic separation and purification to obtain a pure product of the compound isoflavone. The method provided by the invention is used for preparing medical isoflavones such as ipriflavone, formononetin, isoflavoues aglycone, genistein, puerarin and the like, provides a new technical way to the industrial production of the medicines, and is also used for preparing a series of new isoflavone compounds with potential physiological activity.

The invention relates to the new usage of formononetin-3'-sodium sulfonate, and provides the application of the formononetin-3'-sodium sulfonate in the preparation of medicine for treating or preventing cardiovascular disease. The invention more particularly relates to the application of the formononetin-3'-sodium sulfonate in the preparation of medicine for treating or preventing coronary heart disease, angina pectoris or myocardial infarction. The formononetin-3'-sodium sulfonate remarkably reduces the rise of acute myocardial ischaemia rat limb lead electrocardiogram J point, and the ischemic area.

The invention provides application of formononetin in preparing drug for treating pulmonary fibrosis, which is the novel application of formononetin. According to the invention, the formononetin has good effect for pulmonary fibrosis, has no adverse reaction, can slow down the pulmonary fibrosis of mice induced by the bleomycin and has a good application prospect for treating, slowing down or improving the pulmonary fibrosis.

The invention relates to a synthesis method of formononetin, and the method comprises the following steps: condensation: in a dry reactor, adding resorcin, p-metoxybenzene acetate, boron trifluoride and ethyl ether, heating for reaction, adding water after the reaction finishes, heating under reflux, cooling to precipitate crystals, filtering, washing with water until the solution is neutral, and drying to obtain an intermediate; and cyclization: in a dry reaction tank, adding the intermediate, triethyl orthoformate, morpholine, DMF (dimethyl formamide) and glacial acetic acid, separating out the reaction byproduct ethanol, heating under reflux, recycling the DMF reagent under reduced pressure after the reaction finishes, cooling, adding saturated sodium bicarbonate solution into the remainder, refluxing, cooling to precipitate crystals, carrying out conventional treatment to obtain crude formononetin, and refining the crude formononetin by using methanol to obtain the fine formononetin. The method can be used for solving the problem of formononetin resource shortage at present, has the advantages of accessible raw materials, efficient reaction, convenience and high application value.

The invention discloses a quality analysis method for loins-strengthening and kidney-invigorating oral liquid. The content of formononetin is measured by high performance liquid chromatography (HPLC), and the method comprises the steps of: preparing test solution, preparing reference solution and measuring. The method controls quality of the loins-strengthening and kidney-invigorating oral liquid by measuring the content of formononetin in the loins-strengthening and kidney-invigorating oral liquid through the HPLC, has high sensitivity, high specificity, no interference on negative control, has the accuracy, repeatability, linear relation and stability which can meet the requirements of scientific research and production, can more effectively control the product quality, and ensures the curative effect of medicaments.

The invention provides a CAR-NK cell culture method. The culture method comprises the following steps of S1, collecting peripheral blood of a healthy donor, and separating to obtain peripheral blood mononuclear cells; S2, sorting out NK cells from peripheral blood mononuclear cells; S3, infecting the NK cells in the step S2 with a lentiviral vector with a chimeric antigen receptor gene; and S4, carrying out multiplication culture on the CAR-NK cells by using a culture medium containing interleukin-2, inositol, quercetin glucoside, formononetin, sheep placenta and galactose to obtain a large number of CAR-NK cells. The CAR-NK cell culture method disclosed by the invention is simple to operate, and the cultured NK cells are high in purity, large in quantity, large in quantity of CAR-NK cellsand high in killing activity.

The invention relates to the field of medicinal chemistry, formononetin fatty ether derivatives and preparation methods and medical application thereof, in particular to formononetin fatty ether derivatives which have the general formula (I) (please see the general formula in the description) and preparation methods thereof, a pharmaceutical composition containing the compounds, medical application of the compounds and particularly application of the compounds serving as drugs for preventing or treating hyperlipidaemia or obesity or II type diabetes.

The invention discloses a method for inspecting quality of Gueldenstaedtia delavayi Franch. In the inspection method of the Gueldenstaedtia delavayi Franch., by screening a mobile phase under an isochromatic spectrum condition, the separation degree of Formononetin and maackiain chromatographic peaks is enabled to be good. Moreover, the determination method has good repeatability, is stable and reliable and is suitable for the determination of content of Formononetin and maackiain in the Gueldenstaedtia delavayi Franch. According to experiments, the Gueldenstaedtia delavayi Franch. which is inspected as acceptable by adopting the method has good pharmacological activity. The result clearly shows that the inspection method provided by the invention facilitates the realization of the quality control of the Gueldenstaedtia delavayi Franch.

The invention relates to a method for evaluating honeysuckle characteristics based on marker flavonoids screened by metabolome. According to the invention, the method comprises the steps: employing the flavonoid components and the content of the flavonoid components of flower buds/flowers of honeysuckle in different development stages by virtue of an LC-MS/MS technology; quantitatively analyzing the flavonoid difference in different development stages and screening the labeled flavonoid substances in each development stage of the medicinal bud stage, so as to judge the flavonoid category and content of the fresh honeysuckle raw material. The screened formononetin and 7-oxomethyl quercetin can be used as specific marker flavonoid substances in the optimal medicinal bud stage (the second white stage); the 2, 6-gingerol can be used as a specific marker flavonoid substance in the three-green stage, and the peach aglycone can be used as a specific marker flavonoid substance in the large white stage. The invention also provides a basis for extraction and quantitative detection of honeysuckle flavonoids of different cultivated varieties in different cultivation regions, and provides an evaluation method for judging the flavonoid substance characteristics of fresh honeysuckle samples.

The invention provides a whitening cream based on natural extracts. The whitening cream comprises, by weight, 0.4 to 0.6 part of superoxide dismutase, 1 to 3 parts of anthocyanin, 0.2 to 0.25 part of fructus schisandrae chinensis, 0.30 to 0.35 part of lumbricus peptide, 0.3 to 0.4 part of catalase, 1 to 3 parts of astaxanthin, 3 to 5 parts of resveratrol oligomer, 6 to 7 parts of formononetin, and 15 to 18 parts of an emulsifier. The invention also provides a preparation method of the whitening cream based on natural extracts.